Richard Pieri, MD
Infectious Disease · El Paso, TXNPI 1760433924
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 24 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 5 manufacturers reported payments, led by AbbVie at 39.3% of the total. Reporting peaked in 2019 at $381 and has fallen 66.1% since, to $129 in 2025. That places this record below the midpoint for infectious disease clinicians in TX, where the typical reported total is $451.
Across 24 payments — averaging $24.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$234
- Insmed, Inc.$145
- Angiodynamics, Inc.$129
- Medtronic$66
- Shire North American Group Inc$20
What the payments were for
- Food & beverage$594100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 20 | $234 |
| Insmed, Inc. | 1 | $145 |
| Angiodynamics, Inc. | 1 | $129 |
| Medtronic | 1 | $66 |
| Shire North American Group Inc | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$594 in reported general payments places this provider in the 50th percentile of 576 infectious disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Daptomycin | 137 | $33,466 |
| Cefepime Hcl | 116 | $26,234 |
| Meropenem | 84 | $22,997 |
| ErtapenemErtapenem Sodium | 67 | $19,655 |
| Vancomycin Hcl | 109 | $13,861 |
| CeftriaxoneCeftriaxone Sodium | 152 | $7,265 |
| Cefazolin Sodium | 38 | $2,659 |
| Linezolid | 18 | $1,850 |
| Fluconazole | 27 | $1,477 |
| Sodium Chloride0.9 % Sodium Chloride | 59 | $1,423 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 63 | $1,036 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 73 | $842 |
| Cephalexin | 50 | $761 |
| Ciprofloxacin Hcl | 34 | $662 |
| Doxycycline Hyclate | 29 | $584 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in El Paso
- Ogechika AlozieEl Paso$834K
- Suresh AntonyEl Paso$84K
- Nishaal AntonyEl Paso$13K
- Rhonda FlemingEl Paso$10K
- Elizabeth RaceDallas$1.5M
- Joseph GatheHouston$695K
- Roy ChemalyHouston$686K
- Cedric SpakFort Worth$427K
- Ben BarnettHouston$424K
- Uriel SandkovskyDallas$320K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.